
PhaseV is a Boston-based technology company that leverages advanced causal machine learning and GenAI, augmented by an expansive data lake and real-world data (RWD), to empower biopharma sponsors and CROs with fast, accurate, and efficient clinical development decisions. The company offers a comprehensive suite of AI-powered solutions that optimize every phase of the clinical trial process, helping clients to rapidly design and implement adaptive and Bayesian clinical trials, analyze data for heterogeneous treatment effects, and improve trial planning. With over 30 biopharma and CRO customers and a commitment to transforming clinical development, PhaseV is positioned to bring new treatments to patients more efficiently.

PhaseV is a Boston-based technology company that leverages advanced causal machine learning and GenAI, augmented by an expansive data lake and real-world data (RWD), to empower biopharma sponsors and CROs with fast, accurate, and efficient clinical development decisions. The company offers a comprehensive suite of AI-powered solutions that optimize every phase of the clinical trial process, helping clients to rapidly design and implement adaptive and Bayesian clinical trials, analyze data for heterogeneous treatment effects, and improve trial planning. With over 30 biopharma and CRO customers and a commitment to transforming clinical development, PhaseV is positioned to bring new treatments to patients more efficiently.
Founded: 2023
Headquarters: Cambridge / Boston, MA
Sector: AI/ML for clinical trial optimization (biopharma/CRO)
Customers: 30–45+ biopharma and CRO customers (company claims)
Funding: Series A on 2025-05-13; total funding reported ~$65M
Clinical trial design and operations optimization, subgroup/heterogeneous treatment effect analysis, adaptive and Bayesian trial implementation.
2023
Pharmaceutical Manufacturing
Seed round participation included Viola Ventures
Series A reported as led by Accel and Insight Partners
“Participation from Accel, Insight Partners, Exor Ventures, Viola Ventures, LionBird”
| Company |
|---|
The Position
We're seeking a talented, experienced Product Manager to join our Tel Aviv team. In this role, you'll tackle the thrilling challenge of building an intuitive, efficient platform that redefines how clinical trials are designed and conducted, leveraging AI and innovation to transform drug development. You'll collaborate closely with our engineering, data science, algorithm research, and clinical teams to create and refine a state‑of‑the‑art trials platform. This is a rare opportunity to make a tangible impact on how new therapies reach patients and to revolutionize healthcare delivery.
Key Responsibilities
Required Qualifications
About Us PhaseV (HQ in Boston, R&D in Tel Aviv) is a fast-moving startup redefining clinical trial design with a cloud-native, AI-first platform. Founded in 2023, we combine causal machine learning, adaptive trial design, and real-world data to deliver smarter, faster, and more efficient drug development.
Backed by a $50 million Series A, we're enabling sponsors, biotechs, and CROs to uncover hidden insights, optimize trial scenarios in real time, and accelerate the path from molecule to medicine.
At PhaseV, every innovation has one destination: speeding critical treatments from lab to patient.